EUVIMEDEUVIMED entdecken
Crossref

Gut Microbiome Signatures Differ in Cirrhosis With and Without Hepatocellular Carcinoma in a Southeast Asian Cohort

Thananya Jinato, Masoumeh Sikaroodia, Patrick M Gilleveta, Thasinas Dissayabutra, Pisit Tangkijvanich, Jasmohan S Bajaj iD, Natthaya Chuaypen iD

Journal of Gastroenterology and Hepatology · 2026

DOI: 10.1111/jgh.70358 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2026. Verfasst von Thananya Jinato und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Cirrhosis, Liver Neoplasms, Gastrointestinal Microbiome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Second Century Fund, Ratchadapiseksompotch Fund, Faculty of Medicine Chulalongkorn University, Thailand Science research and Innovation Fund Chulalongkorn University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gut microbiota, microbial metabolites, and inflammatory cytokines play key roles in the pathogenesis of cirrhosis and hepatocellular carcinoma (HCC); however, data from Southeast Asia are limited. This study examined microbial composition, intestinal permeability, butyrate‐related gene expression, and cytokine profiles in Thai patients with cirrhosis, with and without HCC.

Methods

This cross‐sectional study included 30 healthy controls, 33 patients with cirrhosis without HCC, and 44 patients with HCC (HCC–cirr). Fecal samples were analyzed using 16S rRNA sequencing. Microbial functional profiles were predicted using KEGG Orthology–based pathway inference. Gut permeability markers (intestinal fatty acid–binding protein [I‐FABP] and lipopolysaccharide‐binding protein [LBP]), butyrate‐associated gene (BCoAT) expression, and cytokine profiles were assessed.

Results

Alpha diversity (Chao1) was significantly lower in HCC–cirr patients than in healthy controls ( p < 0.001) and patients with cirrhosis ( p = 0.008). Beta diversity also differed significantly between HCC–cirr and controls ( p = 0.008). Ligilactobacillus , Catenibacterium , and Alloprevotella were enriched in the cirrhosis group, whereas HCC–cirr patients showed increased Ruminococcus gnavus and reduced butyrate producers ( Coprococcus , Subdoligranulum ). Functional prediction suggested pathway differences between cirrhosis and HCC–cirr, including folate, sulfur, tyrosine metabolism, and steroid biosynthesis. BCoAT expression was significantly decreased in HCC ( p = 0.006). Plasma LBP and I‐FABP were significantly elevated in HCC–cirr ( p = 0.033, p < 0.001), with I‐FABP also higher than in cirrhosis ( p = 0.002). Proinflammatory cytokines (GM‐CSF, IL‐10, IL‐18, IL‐1α, IL‐7, IL‐8, and M‐CSF) were elevated in HCC–cirr.

Conclusions

Among the Thai cohort, HCC with cirrhosis was associated with distinct gut microbial changes, reduced BCoAT expression, increased gut permeability, and cytokine alterations, highlighting the contribution of gut dysbiosis and microbial by‐products to liver disease progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver CirrhosisLiver NeoplasmsGastrointestinal MicrobiomeHumansMaleFemaleMiddle AgedCross-Sectional StudiesCytokinesButyratesFatty Acid-Binding ProteinsThailandFecesLipopolysaccharide-Binding ProteinCohort StudiesAgedCarrier ProteinsIntestinal Barrier FunctionAdultAcute-Phase Proteins

Stichwörter der Autor:innen

HCCbutyrategut microbiotagut permeabilitymetabolite biomarkers

Substanzen

CytokinesButyratesFatty Acid-Binding ProteinsLipopolysaccharide-Binding ProteinCarrier ProteinsAcute-Phase Proteins

Autor:innen und Institutionen

  • Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Center of Excellence in Kidney-Liver-Microbiota, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Mahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Microbiome Analysis Center, George Mason University, Manassas, Virginia, USA.
  • Center of Excellence in Hepatitis and Liver Cancer, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, Virginia, USA.

ORCID-Profile: Jasmohan S Bajaj, Natthaya Chuaypen

Förderung

  • Second Century Fund
  • Ratchadapiseksompotch Fund, Faculty of Medicine Chulalongkorn University
  • Thailand Science research and Innovation Fund Chulalongkorn University
  • Fundamental Fund 2025
  • Program Management Unit for Human Resources & Institutional Development, Research and Innovation

Zitieren

APA

Jinato, T., Sikaroodia, M., Gilleveta, P. M., Dissayabutra, T., Tangkijvanich, P., Bajaj, J. S., & Chuaypen, N. (2026). Gut Microbiome Signatures Differ in Cirrhosis With and Without Hepatocellular Carcinoma in a Southeast Asian Cohort. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70358

Vancouver

Jinato T, Sikaroodia M, Gilleveta PM, Dissayabutra T, Tangkijvanich P, Bajaj JS, et al. Gut Microbiome Signatures Differ in Cirrhosis With and Without Hepatocellular Carcinoma in a Southeast Asian Cohort. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70358

BibTeX
@article{Jinato2026,
  author = {Jinato, Thananya and Sikaroodia, Masoumeh and Gilleveta, Patrick M and Dissayabutra, Thasinas and Tangkijvanich, Pisit and Bajaj, Jasmohan S and Chuaypen, Natthaya},
  title = {Gut Microbiome Signatures Differ in Cirrhosis With and Without Hepatocellular Carcinoma in a Southeast Asian Cohort},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2026},
  doi = {10.1111/jgh.70358}
}
Kostenlos starten →